The Global Strategic Conference of Beroni Group was held successfully in Tokyo, Japan from 30th September 2018 to 4th October 2018, which were attended by Mr. Jacky Zhang, Executive Chairman of Beroni Group, other directors and senior management from Australia, Japan and China.
A key objective of the conference was an evaluation of the current organization structure and business development plans in the countries where the Group has a business presence. The strategic conference also involved evaluating the current business situation against a number of product and market development strategies with a view to developing a robust and sustainable five-year business plan for the Group.
Based on this strategic plan, Beroni aspires to become a world’s leading biotechnology company contributing significantly to improving the human health. Its new strategy will focus on developing 5 pillars of the business, including strengthening the board and management team, diversifying its products and expanding into new markets, becoming a billion dollar value company, collaborating with strategic partners to develop new technologies and expand existing businesses and establishing a strong brand name and reputation.
In addition, the outcome of this review led to a realignment of its business model which are now re-organized into four core businesses:
Firstly, to carry out scientific research and innovation in the field of precision medicine, especially in developing and innovating the cell therapy business. Beroni Group plans to expand the cell therapy business through Beroni Japan and Youtokukai’s Ginza Medical Clinic.
Secondly, to develop new anti-cancer drugs. As part of its collaboration with the University of NSW, Beroni is investing in the development of a new anti-cancer drug PENAO which will commence Phase Ⅱ clinical trial next year. Beroni will be on the look-out for opportunities to develop new anti-cancer drugs with other medical research institutions.
Thirdly, to develop diagnostic tools for detecting infectious diseases. Through its research sponsorship with Columbia University, Beroni is working to secure the distribution rights to six markets namely Australia, Saudi Arabia, USA, China, Japan and India for the distribution of the CII-ArboViroPlex rRT-PCR assay, a diagnostic kit used to detect viruses such as Zika, Dengue, Chikungunya and West Nile.
Fourthly, to establish a strong e-commerce platform for sales of pharmaceutical and healthcare products. Medicine Plus, an affiliate of Beroni Group, provides a wide range of medical drugs, health foods, supplements, cosmetic products and household goods in the Japanese market. Its products are sold to over 2,000 distributors and 7,500 sales outlets, such as chemists, clinics, dentists, supermarkets and other retail outlets. Its e-commerce business is the fastest growing of its sales channels, with an existing membership base of almost 850,000 consumers. In addition, MP also has a significant presence on the popular e-commerce sites in Japan such as Rakuten, Yahoo and Amazon. Beroni Group will help MP promote its third-party marketing business using its outstanding e-commerce’s operational experience and efficient warehouse logistics & delivery management system. At the same time, Beroni Group will expand the sales of its pharmaceutical and healthcare products through its established e-commerce platform in Japan and China to other countries in Asia.
Beroni’s Executive Chairman Mr. Jacky Zhang said the new strategy, by leveraging its business presence in Japan, USA, Australia and China, would lead to an acceleration of growth and internationalisation of the business of Beroni Group. The Chinese domestic medical biotechnology sector has enjoyed dynamic growth in the last few years due to a combination of policy support, industry regulation and sizable capital market. As part of its Made in China 2025 strategic plan, the Chinese government has targeted the rapid development of high-tech fields, including the pharmaceutical industry, from 2015 to 2025. Beroni will take advantage of its new technologies and international connections to fast track the development of its core businesses in the massive Chinese market, Zhang was quoted as saying in his speech.
The conference has effectively evaluated the issues currently faced by the Group and discussed the various solutions. Upholding the principle of seeking truth from facts, the directors, chief scientists, and senior management were able to speak out freely and honestly, and worked together to devise a future plan for Beroni Group. It has turned out to be a successful and rewarding conference.